key: cord-272742-q37xxkja
authors: Mei‐Zahav, Meir; Amirav, Israel
title: Aerosol treatments for childhood asthma in the era of COVID‐19
date: 2020-06-08
journal: Pediatr Pulmonol
DOI: 10.1002/ppul.24849
sha: 
doc_id: 272742
cord_uid: q37xxkja

nan

To the Editor, About 10% of children in the United States have asthma and aerosols are the cornerstone of treatment of asthma. Nebulizers (wet or jet) are one of the commonly used aerosol-generating medical devices and generate small particles that can spread to a larger distance than a normal breath. 1 The particles can also stimulate the patient's or any by-stander's cough mechanisms, which increase the risk of disease spread. This risk is linked not only to patients in medical facilities (offices, emergency departments, etc) who proved infected but to any patient with respiratory symptoms regardless of their infectious status. In conclusion, given that MDI/VHC has been shown to be as effective in numerous clinical situations, switching from nebulization to MDI/VHC treatment should be another important step that pediatricians can take in reducing COVID-19 spread, particularly among health caregivers.

Meir Mei-Zahav MD 1, 2 Israel Amirav MD 2,3,4 1

Factors involved in the aerosol transmission of infection and control of ventilation in healthcare premises

Prevention and control of influenza during a pandemic for all healthcare settings

Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1 N

Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma

The Canadian Paediatric Society Practice Point. Paediatric asthma and COVID-19